| Irbesartan | diabetes type 2, in all type of patients | vs placebo | microvascular events by 25% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 0.91 [0.72 1.15] | p=1.00 | 0 | 1148 | 1 | IDNT (irbesartan vs pbo), | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | microvascular events | 0.75 [0.63 0.91] | p=0.04 | 0 | 1738 | 2 | IPDM (150mg), IDNT (irbesartan vs pbo), | | Non fatal MI | no data | | All cause death | 0.92 [0.69 1.23] | p=1.00 | 0 | 1148 | 1 | IDNT (irbesartan vs pbo), | | Non fatal stroke | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| IPDM (150mg), 2001 | irbesartan 150 mg daily | placebo | hypertensive patients with type 2 diabetes and microalbuminuria | | IDNT (irbesartan vs pbo), 2001 | Irbesartan 300 mg daily | placebo | hypertensive patients with nephropathy due to type 2 diabetes
|
| |
| Irbesartan | | vs amlodipine | microvascular events by 23% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 1.03 [0.81 1.31] | p=1.00 | 0 | 1146 | 1 | IDNT (irbesartan vs amlodipine), | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | microvascular events | 0.77 [0.63 0.94] | p=0.04 | 0 | 1146 | 1 | IDNT (irbesartan vs amlodipine), | | Non fatal MI | no data | | All cause death | 1.04 [0.77 1.40] | p=1.00 | 0 | 1146 | 1 | IDNT (irbesartan vs amlodipine), | | Non fatal stroke | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| IDNT (irbesartan vs amlodipine), 2001 | Irbesartan 300 mg daily | amlodipine 10 mg daily | hypertensive patients with nephropathy due to type 2 diabetes
|
| |
| Losartan | diabetes type 2, in all type of patients | vs placebo | microvascular events by 21% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | microvascular events | 0.79 [0.66 0.95] | p=0.04 | 0 | 2275 | 1 | RENAAL, | | Non fatal MI | no data | | All cause death | 1.02 [0.80 1.30] | p=1.00 | 0 | 2275 | 1 | RENAAL, | | Non fatal stroke | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| RENAAL, 2001 | losartan 50 to 100 mg once daily | placebo | patients with type 2 diabetes and nephropathy |
| |
| Olmesartan | diabetes type 2, in all type of patients | vs placebo | Cardiovascular death by 312% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| macrovascular events | 0.88 [0.62 1.24] | p=1.00 | 0 | 4447 | 1 | ROADMAP, | | Cardiovascular death | 4.12 [1.68 10.11] | p=0.04 | 0 | 5013 | 2 | ROADMAP, ORIENT, | | Non fatal MI | 0.61 [0.35 1.06] | p=1.00 | 0 | 5013 | 2 | ROADMAP, ORIENT, | | All cause death | 1.29 [0.82 2.03] | p=1.00 | 0 | 5013 | 2 | ROADMAP, ORIENT, | | Non fatal stroke | 1.16 [0.61 2.18] | p=1.00 | 0 | 5013 | 2 | ROADMAP, ORIENT, |
| Trial | Studied treatment | Control | Patients |
|---|
| ROADMAP, 2010 | olmesartan at 40 mg/day | placebo | patients with diabetes and at least one additional cardiovascular risk factor, but no evidence of renal dysfunction | | ORIENT, | olmesartan | placebo | patients with diabetic Nephropathy and overt proteinuria secondary to type 2 diabetes mellitus |
| |
| Captopril | diabetes type 2, in all type of patients | vs control | stroke (fatal and non fatal) by 42% suggested microvascular events by 35% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 0.80 [0.57 1.11] | p=1.00 | 0 | 1148 | 1 | UKPDS 38, | | stroke (fatal and non fatal) | 0.58 [0.36 0.93] | p=0.04 | 0 | 1148 | 1 | UKPDS 38, | | microvascular events | 0.65 [0.44 0.95] | p=0.04 | 0 | 1148 | 1 | UKPDS 38, | | Non fatal MI | no data | | All cause death | 0.83 [0.61 1.13] | p=1.00 | 0 | 1148 | 1 | UKPDS 38, | | Non fatal stroke | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| UKPDS 38, 1998 | tight control of blood pressure aiming at a BP <150/85 (with the use of captopril or atenolol as main treatment, other treatment were added if the control criteria were not met) | less tight control aiming at a blood pressure of <180/105 (avoiding treatment with ACE inhibitors or beta-blockers) | hypertensive patients with type 2 diabetes
|
| |
| Captopril | | vs atenolol | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 1.19 [0.79 1.79] | p=1.00 | 0 | 758 | 1 | UKPDS 39, | | stroke (fatal and non fatal) | 1.38 [0.72 2.66] | p=1.00 | 0 | 758 | 1 | UKPDS 39, | | microvascular events | 1.28 [0.77 2.12] | p=1.00 | 0 | 758 | 1 | UKPDS 39, | | Non fatal MI | no data | | All cause death | 1.14 [0.78 1.66] | p=1.00 | 0 | 758 | 1 | UKPDS 39, | | Non fatal stroke | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| UKPDS 39, 1998 | captopril 25 mg/d aiming at a BP <150/85 | atenolol 50mg/d aiming at a BP <150/85 | hypertensive patients with type 2 diabetes |
| |
| Captopril | | vs diuretic and/or beta-blockers | cardiovascular events by 41% suggested myocardial infarction (fatal and non fatal) by 62% suggested All cause death by 46% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 0.59 [0.38 0.91] | p=0.04 | 0 | 572 | 1 | CAPP (diabetic subgroup), | | Cardiovascular death | 0.48 [0.21 1.10] | p=1.00 | 0 | 572 | 1 | CAPP (diabetic subgroup), | | myocardial infarction (fatal and non fatal) | 0.38 [0.19 0.76] | p=0.04 | 0 | 572 | 1 | CAPP (diabetic subgroup), | | stroke (fatal and non fatal) | 1.03 [0.55 1.94] | p=1.00 | 0 | 572 | 1 | CAPP (diabetic subgroup), | | microvascular events | no data | | Non fatal MI | no data | | All cause death | 0.54 [0.31 0.95] | p=0.04 | 0 | 572 | 1 | CAPP (diabetic subgroup), | | Non fatal stroke | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| CAPP (diabetic subgroup), 1999 | Captopril initial dose of 50 mg daily given in one or two doses | thiazide diuretic or beta-blocker | Patients aged 25-66 years with a measured diastolic blood pressure of 100 mm Hg or more on two occasions; subgroup of diabetic patients |
| |
| Lisinopril | diabetes type 2, in all type of patients | vs chlorthalidone | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 1.07 [0.99 1.15] | p=1.00 | 0 | 8740 | 1 | ALLHAT (lisi vs chlor, diabetic subgroup), | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 1.03 [0.94 1.13] | p=1.00 | 0 | 8740 | 1 | ALLHAT (lisi vs chlor, diabetic subgroup), | | stroke (fatal and non fatal) | 1.06 [0.89 1.26] | p=1.00 | 0 | 8740 | 1 | ALLHAT (lisi vs chlor, diabetic subgroup), | | microvascular events | no data | | Non fatal MI | no data | | All cause death | 0.99 [0.89 1.10] | p=1.00 | 0 | 8740 | 1 | ALLHAT (lisi vs chlor, diabetic subgroup), | | Non fatal stroke | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| ALLHAT (lisi vs chlor, diabetic subgroup), 2002 | lisinopril 10 to 40 mg/d | chlorthalidone 12.5 to 25 mg/d | diabetic (subgroup) participants aged 55 years or older with hypertension |
| |
